Key Metrics of Regentis Biomaterials Ltd.
Revenue—FY 2023
Operating income−$1.9M
Net profit−$4.1M
Shareholders' equity−$45.9M
Market cap$9.6MRGNT · $1.37
Competitors10identified
About Regentis Biomaterials Ltd.
Sectors
Company details
- Website
- regentis.co.il
- Founded
- 2025
- Listed
- NYSE: RGNT (since 2025)
Operational Areas of Regentis Biomaterials Ltd.
Pharmaceuticals & Healthcare›Biotechnology & Vaccines
Company summary
Legal nameRegentis Biomaterials Ltd.
TickerRGNT
ExchangeNYSE
CountryIsrael
SEC CIK0001912966
Listed since2025
IndustryIndustrial Specialties
SectorPharmaceuticals & Healthcare · Biotechnology & Vaccines
Websitehttp://www.regentis.co.il
US market & SEC filings
RGNT · NYSE · SEC CIK 0001912966
Last price · 03 Nov 2026
$1.37
+0.00%
Market cap$9.6M
P/E—On FY 2023 diluted EPS
Volume15,303
SectorHealth CareIndustrial Specialties
Country · IPOIsraelListed 2025
RGNT share price
Premium
Annual results (SEC EDGAR)
Revenue, operating income, net income, EPS, cash flow, assets, liabilities, equity and debt for every year filed with the SEC are part of the premium plan.
Sign in to continue See plans & pricingVendor checks & payment capacity
Sign in with access to company financials to review vendor evidence.
Registered office and contact
Registered officeOr Akiva
GSTIN—
Email—
Websitehttp://www.regentis.co.il
Members / shareholders—
Directors and key people
Directors are read from the MGT-7 annual return and AOC-4 signatories.
Competitors of Regentis Biomaterials Ltd.
Competitors10identified
Countries2most in United States
Top competitors by location
| Company | Description | Domain | Founded | Location |
|---|---|---|---|---|
| Part of Vertex Pharmaceuticals. | vrtx.com | 1991 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | gsk.com | 2022 | United Kingdom | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | modernatx.com | 2018 | United States | |
 Becton Dickinson |
Biotechnology & Vaccines · Pharmaceuticals & Healthcare | bd.com | — | United States |
| Part of Illumina. | illumina.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | guardanthealth.com | 2018 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | exelixis.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | revvity.com | — | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | neurocrine.com | 1996 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | biomarin.com | 1999 | United States |
Charges (secured borrowings)
0 registered charges. Lenders, amounts and dates are part of the premium plan.
Statutory auditors
Auditors are read from the AOC-4 auditor's report section.
Business activities and related parties
Principal business activities and related-party transactions are read from MGT-7 and AOC-4 filings.
Filings
No filings on record yet.